Tykerb Tablet
Product Images NDC 0078-0671

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tykerb (NDC 0078-0671). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lapatinib Ditosylate Monohydrate Chemical Structure (Tykerb Spl Graphic 01)

FDA Label Image

Figure 1 (Tykerb Spl Graphic 02)

FDA Label Image

Figure 2 (Tykerb Spl Graphic 03)

FDA Label Image

Figure 3 (Tykerb Spl Graphic 04)

FDA Label Image

Bottle Label (Tykerb Spl Graphic 05)

Bottle Label (Tykerb Spl Graphic 05)
This is a description of a medication package. The medication is lapatinib, which comes in tablet form with each tablet containing 358 mg of lapatinib ditoylte, equivalent to 250 mlapati. The recommended dosage is not provided, and users should refer to the prescribing information. The medication should be stored at temperatures between 20°C and 25°C, with excursions permitted between 15°C and 30°C. The package includes 150 tablets distributed by Novartis Pharmaceuticals Corp, located in New Jersey, USA. The product has a unique identifier code, NDC 0078-0671-19. It also includes instructions for healthcare professionals to use safety closures.*
FDA Label Image

Tykerb Spl Graphic 06

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.